Table 2.

Changes in health-related quality of life, patient functioning and disability scores during treatment (Overall [Months 1–12])

	Overall LS mean change from baseline (SE)a
	GMB 120 mg N = 130	GMB 240 mg N = 135
MSQv2.1 total
LS mean change (SE)	28.3 (1.2)	30.3 (1.1)
Diff vs 120 mg (SE)	–	2.00 (1.6)
95% CI	–	− 1.1, 5.0
RF-R
LS mean change (SE)	31.6 (1.2)	33.4 (1.2)
Diff vs 120 mg SE)	–	1.9 (1.6)
95% CI	–	− 1.3, 5.0
RF-P
LS mean change (SE)	22.1 (1.1)	23.3 (1.1)
Diff vs 120 mg (SE)	–	1.3 (1.5)
95% CI	–	− 1.7, 4.2
EF
LS mean change (SE)	28.9 (1.4)	32.0 (1.3)
Diff vs 120 mg (SE)	–	3.1 (1.8)
95% CI	–	− 0.5, 6.6
MIDAS total
LS mean change (SE)	− 33.6 (2.1)	− 32.7 (2.0)
Diff vs 120 mg (SE)	–	0.9 (2.8)
95% CI	–	− 4.7, 6.5
MIDAS number of days missed work or school
LS Mean Change (SE)	− 3.7 (0.5)	− 3.6 (0.4)
Diff vs 120 mg (SE)	–	0.1 (0.6)
95% CI	–	− 1.2, 1.3
MIDAS number of days with reduced productivity at work or school
LS mean change (SE)	− 7.4 (0.6)	− 7.1 (0.6)
Diff vs 120 mg (SE)	–	0.3 (0.9)
95% CI	–	− 1.3, 2.0
MIDAS number of days missed of household work
LS mean change (SE)	− 9.0 (0.6)	− 8.5 (0.6)
Diff vs 120 mg (SE)	–	0.5 (0.8)
95% CI	–	− 1.1, 2.0
MIDAS number of days with reduced productivity in household work
LS mean change (SE)	− 8.4 (0.5)	− 8.0 (0.5)
Diff vs 120 mg (SE)	–	0.4 (0.6)
95% CI	–	− 0.9, 1.7
MIDAS number of days missed family or social events
LS mean change (SE)	− 5.1 (0.5)	− 5.1 (0.4)
Diff vs 120 mg (SE)	–	− 0.1 (0.6)
95% CI	–	− 1.3, 1.2

EF emotional function; GMB galcanezumab; MIDAS migraine disability assessment; MSQv2.1 migraine-specific quality of life questionnaire version 2.1; RF-P role function-preventive; RF-R role function-restrictive; SE standard error

^aAll p-values (within-group improvement) < 0.001